
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.66552
Obstetrics/Gynecology
Radiation Oncology
Oncology
Moderated Hypofractionated Online Adaptive Radiotherapy in Locally Advanced Cervical Cancer: A Case Report
Muacevic Alexander
Adler John R
Zeng Zheng 1
Zhang Fuquan 1
Yan Junfang 1
1 Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHN
Junfang Yan yanjunfang@pumch.cn
10 8 2024
8 2024
16 8 e665522 8 2024
Copyright © 2024, Zeng et al.
2024
Zeng et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/276798-moderated-hypofractionated-online-adaptive-radiotherapy-in-locally-advanced-cervical-cancer-a-case-report
Cervical cancer is one of the most frequent malignant tumors in females. Concurrent chemoradiotherapy is one of the treatment options for cervical cancer. The treatment time of conventional radiotherapy is long. Moderately hypofractionated radiotherapy (MHRT) offers the advantage of shortening the overall treatment duration and enhancing the radiobiological effects on tumors. MHRT shortens the overall treatment duration while enhancing the radiobiological effects on tumors. Previous studies have reported that MHRT of cervical cancer has relatively high toxicity. Daily online adaptive radiation therapy (oART) showed improvements in dosimetry and a decrease in toxicity. To the best of our knowledge, this case was the first reported case of moderated hypofractionated oART used in a cervical cancer patient to date in a prospective clinical trial (NCT05994300). This case serves as a critical reminder that cervical cancer is a potential tumor that may be in MHRT with iterative cone beam computed tomography-guided oART. Further data are needed to confirm the toxicity and efficacy of this technique.

clinical trial
iterative cone beam computed tomography
online adaptive radiation therapy
moderately hypofractionated radiotherapy
cervical cancer
==== Body
pmcIntroduction

Cervical cancer ranks as the fourth most prevalent malignancy among women globally, with over 85% of cases occurring in developing countries [1]. Due to the lack of regular screening, more than half of cervical cancer patients are diagnosed with locally advanced cervical cancer (LACC) in some developing countries [2]. Combined external-beam radiotherapy (EBRT) and brachytherapy with chemotherapy is the treatment of choice in LACC [3]. The total overall radiotherapy time usually lasts eight weeks or more [4]. However, many countries with high incidences of cervical cancer have the most limited access to radiotherapy, and the longtime of treatment has a significant impact on radiotherapy access.

The development of three-dimensional planning, intensity-modulated radiation therapy (IMRT), and image guidance have been some significant technological progress in radiation therapy made over the past 20 years [5]. These advancements have enabled greater precision in treatment and reduced the number of radiotherapy fractions needed for various disease sites [6]. At present, moderately hypofractionated radiotherapy (MHRT) has become the standard treatment for prostate cancer and breast cancer [7,8]. In a single-arm prospective study, 50 patients with stage IB-IIIC1 cervical cancers were treated with EBRT 40 Gy in 16 fractions. Three-year disease-free survival rate and overall survival rate were 92.7% and 90.6%, respectively. Acute grade 3 gastrointestinal toxicity and grade 3 genitourinary toxicity were observed in 10 patients (20%) and three patients (6%), respectively [9]. Therefore, MHRT for cervical cancer is expected to achieve similar efficacy to conventional fractionated radiotherapy, but the current techniques have high toxicity that requires further improvement.

Variations in bladder and rectum filling, along with tumor regression, greatly impact the shape and position of the cervix and uterus [10]. As a result, a large margin is used to guarantee sufficient target volume coverage during radiotherapy [10]. A large planning margin would result in excessive irradiation to normal tissue, causing a higher rate of adverse events [11]. At present, iterative cone beam computed tomography (iCBCT)-guided online adaptive radiation therapy (oART) can decrease the margin and irradiated volume compared to IMRT by accommodating per-fractional variations [12]. Previous studies have demonstrated the dosimetric advantages of reduced margins, resulting in a lower incidence of acute toxicity in cervical cancer patients [13].

Therefore, moderated hypofractionated oART may be a promising treatment in LACC. To the best of our knowledge, moderated hypofractionated iCBCT-guided oART was first implemented for cervical cancer, a practice not previously documented in other studies.

Case presentation

Patient clinical information

A 39-year-old woman was admitted to our hospital for contact vaginal bleeding. She had a histologically confirmed diagnosis of human papillomavirus (HPV) type 16 moderately differentiated positive squamous cell carcinoma of the cervix. A gynecological physical examination revealed the vulva developed normally. The vagina appeared smooth. The cervix exhibited an ulcer-like neoplasm measuring approximately 3 cm in diameter. The uterus was positioned anteriorly and no tenderness. On the left side, there was no extending up to the pelvic wall, while no obvious abnormalities were found on the right side. Routine blood test results, liver function, kidney function, and electrolyte levels were all within normal limits. However, the serum level of squamous cell carcinoma antigen (SCC-Ag) was elevated to 3.3 IU/mL (normal range: 0-2.7 IU/mL), while both carcinoma antigen 125 and carcinoembryonic antigen levels remained normal. The pelvic magnetic resonance imaging (MRI) examination showed a malignant 2.9 x 3.5 x 3.2 cm lesion in the cervix involving left parametria and a left pelvic lymph node 1.4 x 1.5 cm. Positron emission tomography-computed tomography demonstrated a malignant cervical lesion and left pelvic lymph node metastasis, and no distant metastasis was found. According to the International Federation of Gynecology and Obstetrics Staging System, version 2018, the tumor was staged as IIIC1r. According to the American Joint Committee on Cancer TNM Staging System, version 8, it was staged as T2bN1M0 (Stage IIIC1). The case was then discussed in a gynecological multidisciplinary team meeting. The patient was recommended treatment in a phase 1 clinical trial (NCT05994300), and written consent was obtained.

Clinical trial details

NCT05994300 is a prospective, single-institution, phase 1 clinical trial evaluating the clinical efficacy and toxicity of MHRT for patients with biopsy-proven cervical cancer by iCBCT-guided oART. The enrolled patients include patients with stages IB1-IIB and IIIC1 disease, excluding the largest node size is more than 1.5 cm, more than three metastatic lymph nodes, and metastatic lymph nodes located in the common iliac chain. EBRT was performed on the Ethos system (Varian Medical Systems, Palo Alto, CA) in all patients, which is our institution’s iCBCT-guided oART unit. The primary outcome of this study is acute toxicity at three months. The primary outcomes of this study are late toxicity, response evaluation, disease-free survival, overall survival, and quality of life.

Statistical analysis

Statistical analyses were conducted using IBM SPSS Statistics for Windows (version 23.0; IBM Corp, Armonk, NY). Two-sided P-values ≤ 0.05 were considered statistically significant. The mean, median, and standard deviation of the data were determined. If the data were normally distributed, a paired t-test was utilized for statistical analysis; alternatively, the Wilcoxon rank sum test was applied when normality assumptions were not met.

Treatment

This patient received concurrent chemoradiotherapy (CCRT), in which radiotherapy consisted of EBRT with daily iCBCT-guided oART and brachytherapy. The clinical target volume (CTV) contouring was performed according to the Radiation Therapy Oncology Group Consensus Guidelines [14]. CTV of the lymph (CTV-N) encompassed the pelvic lymphatic drainage area, CTV of the uterus (CTV-U) encompassed the uterus, and CTV of the cervix (CTV-C) included the cervix, vagina, and adjacent parametrial regions [15]. Gross tumor volume nodes (GTVnd) included metastatic lymph nodes (Figure 1). A uniform three-dimensional planning margin of 3 mm GTVnd to plan the target volume node (PTV-nd), 5 mm CTV to plan the target volume of the lymph (PTV-N), and to plan the target volume of the cervix (PTV-C) margin was used for CTV-C and CTV-N, and a 10 mm margin was used CTV-U to the generated planned target volume of the uterus (PTV-U). The prescribed dose consisted of 43.55 Gy in 17 fractions and a simultaneous integrated boost of 54.40 Gy in 17 fractions to GTVnd. Dose constraints for critical organs at risk (OARs) were as follows: bladder D50% ≤ 3800 cGy, rectum D50% ≤ 4000 cGy, bowel D2 cc ≤ 4550 cGy, bowel D50% ≤ 1800 cGy, and spinal cord D0.1cc ≤ 4000 cGy, respectively. Nine-field IMRT plans were created using the Ethos treatment planning system.

Figure 1 Example images of axial (A) and sagittal (B) slices of a planned CT scan from the patient.

CTV-N is shown in red, CTV-U is shown in yellow, CTV-C is shown in blue, and GTVnd is shown in magenta.

Abbreviations: CT, computed tomography; CTV-N, clinical target volume of the lymph; CTV-U, clinical target volume of the uterus; CTV-C, clinical target volume of the cervix; GTVnd, gross tumor volume node

During the treatment with oART, the patient received 17 fractions of oART and cooperated fully with the entire adaptive procedure. This included the initial acquisition of iCBCT; influencer generation and editing, as well as the generation and editing of targets and OARs; and finally plan generation and selection. The timing data are shown in Table 1. The adaptive procedure averaged 18 minutes and 34 seconds. After incorporating a second iCBCT scan and treatment, the total average time increased to 23 minutes and 34 seconds.

Table 1 Timing data of online adaptive radiation therapy.

Abbreviations: iCBCT, iterative cone beam computed tomography; OARs, organs at risk

Times (minutes and seconds) consuming	Min	Max	AVG	
Initial acquisition of iCBCT	48 s	59s	52S	
Influencer generation and edits	1 min 01 s	3min21s	2min11s	
Target and OARs generation and edits	5 min 25 s	11min16s	7min40s	
Plan generation and selection	3 min 03 s	6min43s	3min51s	
Second acquisition of iCBCT	45 s	57s	51s	
Treatment	4 min 10 s	4min56s	4min09s	
Online adaptive time	10 min 17 s	22min12s	18min34s	
Total time	15 min 12 s	28min12s	23min34s	

For treatment plan selection, the adapted plan was chosen for all 17 fractions. The adapted plan achieved superior dosimetric coverage of the target volume compared to the scheduled plan (Figure 2). The median V100% values for CTV-N, CTV-C, CTV-U, GTVnd, PTV-N, PTV-C, PTV-U, and PTV-nd were 99.9% versus 99.4% (P = 0.009), 98.4% versus 92.5% (P < 0.001), 99.1% versus 97.8% (P = 0.002), 100.0% versus 99.8% (P = 0.029), 96.9% versus 97.9% (P = 0.357), 93.2% versus 87.6% (P < 0.001), 96.5% versus 93.8% (P < 0.001), and 98.5% versus 96.3% (P = 0.005), respectively.

Figure 2 Comparison of the adapted plan and scheduled plan using iterative cone beam computed tomography-guided oART for this patient with LACC.

Adapted plan (A) and scheduled plan (B) for fraction two of treatment.

Abbreviations: LACC, locally advanced cervical cancer; oART, online adaptive radiation therapy

Table 2 presents the dosimetric results of OARs across all treatment fractions for the patient. In the adaptive plan, the mean dose and D2cc of bowel were 100.0 ± 15.2 cGy and 266.9 ± 0.8 cGy, respectively, which were significantly lower than the doses in the scheduled plan (142.6 ± 29.9 cGy and 268.3 ± 1.2 cGy, respectively). In contrast to the scheduled plan, the adaptive plan demonstrated a significant improvement in rectal dosimetry at V4000 cGy (P < 0.001). However, there was no significant difference in the mean dose and V4000 cGy of the bladder. The dosimetry of the bone marrow was also improved with the adaptive plan.

Table 2 Comparison of the dosimetric outcomes of OARs between the adapted plan and the scheduled plan for the patients.

Abbreviations: OARs, organs at risk

OARs	Goal	Scheduled plan	Adapted plan	P	
Femur head left	D5%(cGy)	143.4±5.7	139.7±9.8	0.202	
Femur head right	D5%(cGy)	144.3±5.7	136.4±21.3	0.322	
Bone marrow	D90%(cGy)	48.4±2.0	37.8±2.8	＜0.001	
Bladder	Dmean (cGy)	146.8±21.7	156.6±21.1	0.207	
 	V4000 cGy(%)	24.6±9.6	21.6±7.6	0.768	
Rectum	Dmean (cGy)	176.9±18.4	163.5±21.8	0.048	
 	V4000 cGy (%)	31.2±6.4	18.6±9.1	＜0.001	
Bowel	Dmean (cGy)	142.6±29.9	100.0±15.2	＜0.001	
 	D2cc (cGy)	268.3±1.2	266.9±0.8	＜0.001	

After the completion of oART, treatment response was evaluated on the basis of the findings of pelvic MRI in accordance with RECIST 1.1 (https://recist.eortc.org/recist-1-1-2/) (Figure 3). The total diameter of the measurable lesion was about 1.1 × 1.8 × 1.2 cm, which is reduced by 56% from the baseline. The total diameter of the target lymph node was about 0.6 × 0.4 cm, which is reduced by 52% from the baseline. The serum level of SCC-Ag was decreased to 2.2 IU/mL (0-2.7 IU/mL). CT-guided high-dose-rate (HDR) brachytherapy generally began after EBRT, and a dose of 30 in five fractions was delivered. Intravenous cisplatin was administered weekly at a dosage of 40 mg/m2 during radiotherapy. Following this, the patient received five cycles of treatment with cisplatin. Moderated hypofractionated oART with HDR brachytherapy appears to be a well-tolerated treatment, and only grade 2 acute hematologic toxicity and grade 1 acute gastrointestinal toxicity were observed. No acute genitourinary toxicity was observed. Pelvic MRI showed that clinical response after one month of CCRT. The overall follow-up time was 10 months, and no local recurrence or distant metastasis happened.

Figure 3 Pelvic MRI images of the patient.

A, D: Pelvic MRI T2 images of the patient before treatment. B, E: Pelvic MRI T2 images of the patient after EBRT. C, F: Pelvic MRI images of the patient one month after treatment.

MRI: magnetic resonance imaging; EBRT: external-beam radiotherapy

Discussion

Here, we presented an LACC patient with stage IIIC, and the size of the tumor was relatively large. After completing treatment with moderated hypofractionated oART, the tumor size decreased significantly. Then, HDR brachytherapy was implemented, and the patient ultimately achieved a clinical response. No grade 3 and more acute toxicity was reported. The overall follow-up time was 10 months, and this patient achieved a continuous recurrence-free survival. For all we know, this is the first reported case of LACC treated with moderated hypofractionated oART.

Radiotherapy is essential in the treatment of cervical cancer, with around 80% of patients receiving radiation therapy either alone or in combination with other treatments [5]. Radiotherapy for cervical cancer includes both EBRT and brachytherapy, which usually lasts eight weeks [4]. However, prolonged treatment duration can lead to insufficient availability of medical resources [6]. MHRT offers the advantage of shortening the overall treatment duration while enhancing the radiobiological effects on tumors [7]. MHRT has been used and become the standard of care in different cancer sites and offers radiobiologic superiority for tissues with a low α/β ratio [7,8]. However, the radiobiological effect of MHRT in cervical cancer remains unknown.

Several studies have reported the outcomes of MHRT for cervical cancer. Muckaden et al. [16] conducted a retrospective analysis of 62 stage IIIB cervical cancer patients who received pelvic irradiation at 39 Gy in 13 fractions combined with brachytherapy. The five-year disease-free survival rate was 59%, with five patients experiencing late grade 3 rectal toxicity [16]. Kavuma et al. [17] showed the treatment outcomes of definitive CCRT utilizing an MHRT regimen of 45 Gy in 15 fractions with two-dimensional radiotherapy, noting that 10%-15% of patients experienced late gastrointestinal toxic effects of grade 3 or higher. More recently, a phase II randomized trial from Iran has compared MHRT of 40 Gy in 15 daily fractions with weekly cisplatin using three-dimensional conformal radiotherapy with the standard treatment of 45 Gy in 25 daily fractions with weekly cisplatin [17]. The results indicated that 66.7% of patients in the standard group and 65.5% in the MHRT group achieved a complete clinical response (P = 0.13). However, the MHRT group experienced a significantly higher incidence of acute grade ≥3 gastrointestinal toxicity (27.6%) compared to the standard group (6.7%) (P = 0.032).

Currently, an ongoing Thai phase II trial is randomizing patients with locally advanced cervical cancer between EBRT with 44 Gy/20 fractions or 45 Gy/25 fractions. EBRT is being delivered with IMRT and weekly concurrent cisplatin. The authors reported grade 2 and more acute gastrointestinal toxicity (50%) and genitourinary toxicity (28%) in the MHRT arm [18]. From two-dimensional radiotherapy to IMRT, the experience of a clinical series of cervical cancer patients treated with MHRT may bring a higher incidence of adverse reactions.

Adaptive radiotherapy, a promising technique for treating cervical cancer, still has many areas that need further exploration. These include margin determination, dosimetry, and toxicity [19]. The previous study found that oART could reduce planning target volume margins to 5 mm in the postoperative treatment of endometrial and cervical cancer, which significantly decreases the dose of critical OARs. Wang et al. [13] evaluated further the clinical implementation of daily iCBCT-guided oART in the postoperative treatment of endometrial and cervical cancer with planning target volume margin reduction to 5 mm [20]. Daily oART also showed improvements in dosimetry. Meanwhile, grade 3 toxicities were observed in only one patient with leukopenia, and no patients experienced acute urinary toxicity. In short, oART has proven beneficial in treating cervical cancer safely.

MHRT is relatively high toxicity; therefore, demonstrating the feasibility of MHRT to cervical cancer using oART is critical to increasing the accessibility of this technique to patients with cervical cancer.

Conclusions

Herein, we described the first reported case of a patient with cervical cancer treated with 43.35 Gy in 17 fractions of CTV and 54.40 Gy in 17 fractions of GTV-nd using oART. Moderated hypofractionated oART with HDR brachytherapy appears to be a very promising treatment in LACC. Further long-term follow-up of this patient and others treated in phase 1 clinical trial (NCT05994300) is needed to assess the duration of response.

Disclosures

Author Contributions

Human subjects: Consent was obtained or waived by all participants in this study. Ethics Committee at Peking Union Medical College Hospital issued approval K4477.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Zheng Zeng, Junfang Yan, Fuquan Zhang

Acquisition, analysis, or interpretation of data:  Zheng Zeng

Drafting of the manuscript:  Zheng Zeng

Critical review of the manuscript for important intellectual content:  Junfang Yan, Fuquan Zhang

Supervision:  Junfang Yan, Fuquan Zhang
==== Refs
References

1 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A 394 424 68 2018 30207593
2 Cancer statistics in China, 2015 CA Cancer J Clin Chen W Zheng R Baade PD 115 132 66 2016 26808342
3 The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer Radiother Oncol Cibula D Pötter R Planchamp F 404 416 127 2018 29728273
4 The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study Oncotarget Lin SM Ku HY Chang TC Liu TW Hong JH 85203 85213 8 2017 29156713
5 Global challenges of radiotherapy for the treatment of locally advanced cervical cancer Int J Gynecol Cancer Mayadev JS Ke G Mahantshetty U Pereira MD Tarnawski R Toita T 436 445 32 2022 35256434
6 Should we embrace hypofractionated radiotherapy for cervical cancer? A technical note on management during the COVID-19 pandemic Radiother Oncol Mendez LC Raziee H Davidson M Velker V D'Souza D Barnes E Leung E 270 273 148 2020 32474128
7 Hypofractionated radiation therapy for localized prostate cancer: an Astro, ASCO, and AUA evidence-based guideline J Clin Oncol Morgan SC Hoffman K Loblaw DA 0 36 2018
8 European Society for Radiotherapy and Oncology Advisory Committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer Lancet Oncol Meattini I Becherini C Boersma L 0 31 23 2022
9 A pilot study of moderately hypo-fractionated whole pelvic radiotherapy with concurrent chemotherapy and image-guided high dose rate brachytherapy for locally advanced cervical carcinoma Int J Radiat Oncol Biol Phys Gandhi AK Rastogi M Yadav UN Mishra VK Srivastava AK Bharati A Mishra SP 0 114 2022
10 Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer Int J Radiat Oncol Biol Phys Lim K Small W Jr Portelance L 348 355 79 2011 20472347
11 Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer Gynecol Oncol Shih KK Milgrom SA Abu-Rustum NR 535 539 128 2013 23174538
12 Online adaptive radiotherapy of anal cancer: normal tissue sparing, target propagation methods, and first clinical experience Radiother Oncol Åström LM Behrens CP Storm KS Sibolt P Serup-Hansen E 92 98 176 2022 36174846
13 Evaluation of PTV margins with daily iterative online adaptive radiotherapy for postoperative treatment of endometrial and cervical cancer: a prospective single-arm phase 2 study Radiat Oncol Wang G Wang Z Guo Y 2 19 2024 38178254
14 NRG oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer: an update Int J Radiat Oncol Biol Phys Small W Jr Bosch WR Harkenrider MM 413 424 109 2021 32905846
15 Pelvic target volume inter-fractional motion during radiotherapy for cervical cancer with daily iterative cone beam computed tomography Radiat Oncol Zeng Z Zhu J Wang Z Wang G Yan J Zhang F 48 19 2024 38622628
16 Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata Memorial Hospital experience Indian J Cancer Muckaden MA Budrukkar AN Tongaonkar HB Dinshaw KA 127 134 39 2002 https://pubmed.ncbi.nlm.nih.gov/12928570/ 12928570
17 A retrospective review of conventional versus hypo-fractionated pelvic radiotherapy for locally advanced cervical cancer, in limited-resource countries: the Uganda experience S Afr J Oncol Kavuma A Luutu I Kibudde S Bangidde C 186 5 2021
18 Hypocx-IREX (TCTR20210812003) a phase II RCT: 44 Gy/20F vs 45 Gy/25F CCRT in cervical cancer: six-month post-RT update Int J Radiat Oncol Biol Phys Prasartseree T Dankulchai P Sittiwong W Thephamongkhol K 0 117 2023
19 Comparison of online-onboard adaptive intensity-modulated radiation therapy or volumetric-modulated arc radiotherapy with image-guided radiotherapy for patients with gynecologic tumors in dependence on fractionation and the planning target volume margin JAMA Netw Open Guberina M Santiago Garcia A Khouya A 0 6 2023
20 Daily online adaptive radiation therapy of postoperative endometrial and cervical cancer with PTV margin reduction to 5 mm: dosimetric outcomes, acute toxicity, and first clinical experience Adv Radiat Oncol Wang G Wang Z Zhang Y 101510 9 2024 38826155
